12 recruiting, 11 completed, 11 unknown, 9 terminated. 52 Phase 2, 14 Phase 1, 1 Phase 3.
Follow Small-cell Lung Cancer: new trials by email Literature Review of Small-cell Lung Cancer trials Research Report on Small-cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) Cirtuvivint, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 42 | 2025-12-18 | 2026-08-12 |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer IDE849, durvalumab, IDE161 - Small-cell Lung Cancer, Neuroendocrine Carcinomas | Phase 1 / Phase 2 | Recruiting | IDEAYA Biosciences | 262 | 2025-10-14 | 2026-07-09 |
| Phase 2 Study of Fingolimod in Lung Cancers Fingolimod 0.5 milligram (mg) [Gilenya] - Non Small Cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Recruiting | Medical University of South Carolina | 38 | 2025-05-01 | 2026-03-30 |
| Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status Tarlatamab - Small-cell Lung Cancer | Phase 2 | Recruiting | AIO-Studien-gGmbH | 57 | 2025-01-01 | 2026-10-26 |
| A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC ivonescimab, irinotecan liposome - Small-cell Lung Cancer | Phase 2 | Completed | Zhejiang Cancer Hospital | 60 | 2024-10-16 | 2026-08-27 |
| Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic Intrathecal Pemetrexed - Small-cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 80 | 2024-10-01 | 2024-09-19 |
| Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide - Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Active not recruiting | BioNTech SE | 110 | 2024-08-05 | 2026-11-06 |
| Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer hypofractionated radiotherapy with immunotherapy - Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Anhui Provincial Hospital | 45 | 2024-07-01 | 2024-09-19 |
| Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study Teniposide, Etoposide, serplulimab - Small-cell Lung Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 90 | 2024-02-01 | 2026-05-13 |
| Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC split-course adaptive hypofractionated radiotherapy - Small-cell Lung Cancer | Phase 2 | Enrolling by invitation | Fujian Medical University Union Hospital | 35 | 2023-12-26 | 2025-02-10 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment Serplulimab, SOC - Small-cell Lung Cancer | Phase 2 | Active not recruiting | Guangdong Association of Clinical Trials | 66 | 2023-07-07 | 2026-07-28 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer JS201 combine with Lenvatinib - Small-cell Lung Cancer | Phase 2 | Unknown | Hunan Province Tumor Hospital | 30 | 2023-06-01 | 2024-09-19 |
| ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers ADI-PEG 20, Gemcitabine, Docetaxel - Non Small Cell Lung Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 31 | 2023-04-05 | 2026-07-27 |
| EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer EP0057, Olaparib tablets - Gastric Cancer, Small-cell Lung Cancer | Phase 2 | Withdrawn | Ellipses Pharma | 2023-04-01 | 2023-06-12 | |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer HLX07, HLX10, carboplatin and etoposide - Small-cell Lung Cancer | Phase 2 | Unknown | Shanghai Henlius Biotech | 20 | 2023-03-29 | 2022-05-04 |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer Carboplatin, Pemetrexed, Paclitaxel - Lung Cancer, Small-cell Lung Cancer | Phase 2 | Recruiting | Fox Chase Cancer Center | 280 | 2023-02-22 | 2026-05-22 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
Showing 20 of 52. Sign in to see all of them.
Small Cell Lung Carcinoma (52) · Carcinoma, Non-Small-Cell Lung (8) · Lung Neoplasms (7) · Carcinoma, Neuroendocrine (4) · Prostatic Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Stomach Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Transitional Cell (3) · Thyroid Neoplasms (3) · Anus Neoplasms (2) · Brain Neoplasms (2) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Cholangiocarcinoma (2)
Bronchial Neoplasms (52) · Carcinoma, Bronchogenic (52) · Lung Diseases (52) · Neoplasms by Site (52) · Respiratory Tract Diseases (52) · Respiratory Tract Neoplasms (52) · Thoracic Neoplasms (52) · Neoplasms (50) · Lung Neoplasms (45) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (11) · Carcinoma (9) · Genital Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8)
Etoposide (16) · Carboplatin (15) · Cisplatin (5) · atezolizumab (5) · durvalumab (5) · Radiosurgery (4) · pembrolizumab (4) · Irinotecan (3) · Paclitaxel (3) · Topotecan (3) · apatinib (3) · Docetaxel (2) · Gemcitabine (2) · Nivolumab (2) · PM 01183 (2)
Shanghai Pulmonary Hospital, Shanghai, China (3) · Fox Chase Cancer Center (2) · Hunan Province Tumor Hospital (2) · TransThera Sciences (Nanjing), Inc. (2) · Washington University School of Medicine (2) · AIO-Studien-gGmbH (1) · Anhui Provincial Hospital (1) · AstraZeneca (1) · BioNTech SE (1) · Brian Henick, MD (1) · Case Comprehensive Cancer Center (1) · Chinese Academy of Medical Sciences (1) · Dwight Owen (1) · EMD Serono Research & Development Institute, Inc. (1) · Ellipses Pharma (1)
United States (27) · China (23) · South Korea (6) · Spain (5) · Australia (3) · Belgium (3) · France (3) · Germany (2) · Italy (2) · Poland (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Canada (1) · Chile (1) · Denmark (1)
ShengFa Su, PhD,MD (2) · Afshin Dowlati, MD (1) · Anish Thomas, MD (1) · Ashish Saxena, MD (1) · Brian Henick, MD (1) · Christine Auberle, M.D. (1) · Christine Bestvina, MD (1) · Dwight Owen, MD, MS (1) · Jared Weiss, MD (1) · Jeffrey Clarke, MD (1) · Jin-Ji Yang, PhD (1) · Jordi Rodon Ahnert, MD, PhD (1) · Julia Judd, DO (1) · Kathryn Beckermann, MD (1)
PMID 10561263, PMID 25230595, PMID 30280641, PMID 33166719, PMID 33234490, PMID 33446664, PMID 36727741, PMID 36907793, PMID 37977903, PMID 39462179, PMID 39941812, PMID 40210967, PMID 40481574
2017 (1), 2025 (1), R01CA273216 (1)